

Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report

Robert Klaassen¹ and Heather Perkins¹

¹Children's Hospital of Eastern Ontario

November 25, 2020

Abstract

Surgery in patients with factor VII (FVII) deficiency may be complicated by severe bleeding, requiring regular bolus doses of replacement therapy. Eptacog alfa (activated) is a recombinant activated FVII (rFVIIa) used for the treatment of bleeds and perioperative management in patients with approved bleeding disorders, including FVII deficiency. We report that using the B-Braun Perfusor® Space syringe pump to automatically deliver regular bolus rFVIIa doses provided effective hemostasis and no safety concerns in a patient with mild FVII deficiency undergoing emergency laparoscopic appendectomy. Additional benefits included saving nursing/hospital resources, reducing treatment burden and reassurance for the patient/family, and healthcare providers.

Hosted file

FVII Deficiency case_(Perkins_Klaassen)_FINAL_23Nov2020_v2.0.pdf available at <https://authorea.com/users/378559/articles/495023-successful-use-of-recombinant-activated-factor-vii-administered-via-automated-bolus-pump-following-emergency-laparoscopic-appendectomy-in-a-patient-with-mild-congenital-fvii-deficiency-case-report>